BioMark Diagnostics Inc.
BUX
CNSX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -82.27% | 3.68% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -82.27% | 3.68% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -82.27% | 3.68% | |||
| SG&A Expenses | 3.19% | -22.49% | |||
| Depreciation & Amortization | -13.50% | -54.08% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.26% | -33.09% | |||
| Operating Income | -27.66% | 35.48% | |||
| Income Before Tax | -16.23% | -2.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -16.23% | -2.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.23% | -2.28% | |||
| EBIT | -27.66% | 35.48% | |||
| EBITDA | -27.91% | 35.75% | |||
| EPS Basic | -13.79% | -3.57% | |||
| Normalized Basic EPS | -16.67% | -5.88% | |||
| EPS Diluted | -13.79% | -3.57% | |||
| Normalized Diluted EPS | -16.67% | -5.88% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||